PCSK9 and atherosclerosis: Secondary prevention trials with both evolocumab and alirocumab suggest similar benefits and safety of PCSK9 inhibition in older (≥65 years of age) and younger individuals.114, 115 To date, there are no large randomized controlled outcomes trials using PCSK9 inhibition for primary prevention of ASCVD.